EVOK Evoke Pharma, Inc.

2.60
-0.01  -0%
Previous Close 2.61
Open 2.60
Price To book 5.06
Market Cap 40.01M
Shares 15,388,000
Volume 46,363
Short Ratio 18.35
Av. Daily Volume 148,105

SEC filingsSee all SEC filings

  1. 8-K - Current report 17844797
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17844522
  3. 8-K - Current report 17828602
  4. 8-K - Current report 17812031
  5. 8-K - Current report 17766075

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint not met. However, the company noted December 15, 2016 that following discussions with FDA regarding possible NDA submission, no new efficacy or safety study would be required, if bioequivalence criteria were met in a pharmacokinetic (PK) trial. Confirmed April 4, 2017 that PK data will be released 2H 2017 with NDA filing to be submitted by late 2017 or early 2018.
Gimoti - EVK-001
Female diabetic gastroparesis

SEC Filings

  1. 8-K - Current report 17844797
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17844522
  3. 8-K - Current report 17828602
  4. 8-K - Current report 17812031
  5. 8-K - Current report 17766075
  6. 8-K - Current report 17736268
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17705736
  8. DEF 14A - Other definitive proxy statements 17705734
  9. 8-K - Current report 17703070
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17691402